Reported about 10 hours ago
Relay Therapeutics, Inc. (NASDAQ:RLAY) is making strides in AI-based oncology with its leading candidate, RLY-2608, a PIK3CA inhibitor currently in late-stage trials for breast cancer. Recent data indicates strong efficacy and safety, garnering positive attention from analysts and positioning it as a leading therapy in precision oncology. The company is also exploring RLY-2608's potential for treating vascular malformations. Collaborations with Pfizer and Elevar Therapeutics are expected to enhance commercialization efforts, as Relay expands its portfolio of small-molecule inhibitors targeting difficult cancers.
Source: YAHOO